Trial Profile
A Multicenter Pilot Study of Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Targeted Immunotherapy in Children, Adolescents and Young Adults With Poor Risk CD30+ Hodgkin Lymphoma (HL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Busulfan; Cyclophosphamide; Fludarabine; Gemcitabine; Melphalan
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 24 Oct 2022 Planned End Date changed from 1 Dec 2020 to 31 Dec 2022.
- 24 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 11 Mar 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.